Details for Patent: 10,828,298

Which drugs does patent 10,828,298 protect, and when does it expire?

Patent 10,828,298 protects UPTRAVI and is included in one NDA.

Protection for UPTRAVI has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-one patent family members in thirty-three countries.

Summary for Patent: 10,828,298

Title:	Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy]-N-(methylsulfonyl)acetamide
Abstract:	A stabilized solid preparation containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide is provided, namely, a solid preparation containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide and D-mannitol having a specific surface area of 1.0 m2/g or less.
Inventor(s):	Shouji FURUTA, Hironori MUKAI
Assignee:	Nippon Shinyaku Co Ltd
Application Number:	US16/044,821
Patent Claim Types: see list of patent claims	Use; Dosage form;

Drugs Protected by US Patent 10,828,298

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Actelion	UPTRAVI	selexipag	TABLET;ORAL	207947-001	Dec 21, 2015	AB	RX	Yes	No					Y
Actelion	UPTRAVI	selexipag	TABLET;ORAL	207947-002	Dec 21, 2015	AB	RX	Yes	Yes					Y
Actelion	UPTRAVI	selexipag	TABLET;ORAL	207947-003	Dec 21, 2015	AB	RX	Yes	No					Y
Actelion	UPTRAVI	selexipag	TABLET;ORAL	207947-004	Dec 21, 2015	AB	RX	Yes	No					Y
Actelion	UPTRAVI	selexipag	TABLET;ORAL	207947-005	Dec 21, 2015	AB	RX	Yes	No					Y

International Family Members for US Patent 10,828,298

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2016366073
Brazil	112018009534
Canada	3005169
Chile	2018001464
China	108289890